R&D Investments, Pending Approvals, Acquisitions - Research Report on Optimer, Zogenix, Cubist, Merck and Questcor PR Newswire NEW YORK, March 4, 2013 NEW YORK, March 4, 2013 /PRNewswire/ -- Today, Investors Alliance announced new research reports highlighting Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR), Zogenix, Inc. (NASDAQ: ZGNX), Cubist Pharmaceuticals Inc (NASDAQ: CBST), Merck & Co., Inc. (NYSE: MRK) and Questcor Pharmaceuticals, Inc. (NYSE: QCOR). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Optimer Pharmaceuticals, Inc. Research Report Optimer shares rallied 13 percent following news that one of its "strategic alternatives to maximize shareholder value" was to consider a possible sale. The company's CEO Pedro Lichtinger will also resign and will be replaced on an interim basis by former Pfizer Inc. CEO Henry A. McKinnell Jr. According to Brian Skorney, an analyst for Robert W. Baird & Co., the company may be a target for Pfizer or Johnson & Johnson. Furthermore, data compiled by Bloomberg states that the company's revenue is projected to more than double to $310 million by the end of 2017 from 2011. Fourth quarter earnings were 2 cents per share against an estimate of a 55 cent loss. With a change in leadership and a possible sale, many analysts and investors are optimistic about Optimer's future. The company's full report will The Full Research Report on Optimer Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/757e_OPTR] -- Zogenix, Inc. Research Report Zogenix announced that the FDA has delayed approval for its Zohydro drug, a long-acting version of the painkiller hydrocone. The FDA did not comment the cause of the delay but stated that it would most likely be brief and may last only for several weeks. Many remain optimistic that the FDA will approve the drug, including Wells Fargo analyst Michael Tong. He comments, "We continue to believe the odds for eventual approval are high. We speculate FDA is dealing with issues of access and potential misuse." If approved, the drug will be the first pure hydrocone medication in the United States, showing the potential of this drug to generate returns for the company. The Full Research Report on Zogenix, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/d33e_ZGNX] -- Cubist Pharmaceuticals Inc Research Report Cubist announced that it has entered into an option agreement with Adynxx in which Cubist will have exclusive right to acquire Adynxx following the data readout of Adynxx's Phase II trial for AYX1. Cubist is impressed with the Phase I results and believes that the drug may be a new therapy for post-surgical and chronic pain. Cubist will pay Adynxx to secure exclusive rights to acquire the company with cash on hand, and additional payments will be made to Adynxx shareholders if Cubist chooses to exercise its right to acquire Adynxx. This is one of Cubist's strategic efforts to strengthen its pipeline. The Full Research Report on Cubist Pharmaceuticals Inc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/0f29_CBST] -- Merck & Co., Inc. Research Report To strengthen its pipeline, Merck has entered into a biosimilars development project and commercialization agreement with Samsung Bioepis Co., Ltd. Biosimilars, or generic biologics, are drugs with active substances made from living organisms. With their combined resources, the two companies aim to promote public access to biosimilars. Furthermore, Merck presented new data regarding its allergic rhinitis treatment. Developing its pipeline allows the company to assure long-term growth and continue returning healthy dividends to investors. Its most recent dividend was announced at 43 cents per share, payable April 5, 2013. The Full Research Report on Merck & Co., Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/d004_MRK] -- Questcor Pharmaceuticals, Inc. Research Report Questcor Pharmaceuticals reported earnings that beat estimates, with adjusted earnings per share of $1.09, up 132 percent from the same quarter a year ago. The company's Acthar drug was the main driver for growth. Acthar sales were up 94 percent compared to 2011. In the coming year, Questcor intends to continue investing in R&D programs and increase manufacturing capabilities. The company is presently working on approximately 35 research projects, including some Phase 4 projects. Lastly, the company has been repurchasing shares in order to provide higher returns to investors. The Full Research Report on Questcor Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/21da_QCOR] -- Consider Investors Alliance Tired of hearing about the latest, greatest trade opportunity... only to realize that the ship has long sailed? You need a strong, informative community in your arsenal. Join the group that has been consistently identifying momentous situations as they develop - long before they become the next top news on major financial networks. Contact: Patricia Byers Email: press@Investors-Alliance.com Main: +1-480-745-7826 SOURCE Investors-Alliance
R&D Investments, Pending Approvals, Acquisitions - Research Report on Optimer, Zogenix, Cubist, Merck and Questcor
Press spacebar to pause and continue. Press esc to stop.